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Introduction
Gene therapy, which involves the use of genetic
material for therapeutic purposes,1 is a new form of
treatment that has appeared in the last decade as a result
of advances in microbiology, virology, organic
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OBJECTIVE: To assess the effectiveness of in vivo gene
therapy to treat subcutaneous tumors generated from murine
lung cancer cells.
MATERIAL AND METHODS: C57BL/6 mice received
subcutaneus injections of 5×105 cells from the murine Lewis
lung cancer cell line. By 10 days, subcutaneous tumors of
approximately 5 mm diameter were formed. At that point,
treatment was provided by intratumor injection of a
replication-defective recombinant adenovirus carrying the
gene for thymidine kinase (AdCMV-Tk) or interleukin (IL)
12 (AdCMV-IL12), or by injection of syngeneic dendritic
cells previously transduced with adenovirus containing the
IL-12 gene (DC-IL12). Control groups were treated with
saline or adenovirus containing the gene for β-galactosidase
(AdCMV-LacZ), which functions as a reporter gene and
does not have a therapeutic effect. The number of animals in
each group ranged from 14 to 25 in experiments using
adenovirus and from 10 to 12 in experiments using dendritic
cells. Tumor size was followed for 3 weeks in the case of
treatment with adenovirus and 4 weeks for treatment with
dendritic cells.
RESULTS: A significant reduction in subcutaneous tumor
growth was observed in the groups treated with AdCMV-
Tk, AdCMV-IL12, and DC-IL12 compared with control
groups treated with saline or AdCMV-LacZ. The difference
was statistically significant from day 7 of treatment in the
AdCMV-Tk group, from day 9 in the AdCMV-IL12 group,
and from day 10 in the DC-IL12 group, and in all cases it
was maintained until the end of the follow-up period.
CONCLUSIONS: Gene therapy with AdCMV-Tk, AdCMV-
IL12, or DC-IL12 is effective in our model of subcutaneous
tumors arising from cells of the Lewis lung cancer cell line.
The treatment leads to a significant reduction in tumor
growth compared with control groups.
Key words: Gene therapy. Lung cancer. Adenovirus. Thymidine
kinase. Interleukin 12. Dendritic cells.
Aplicación de tratamiento oncogénico a un
modelo subcutáneo de cáncer de pulmón murino
OBJETIVO: Demostrar la utilidad del tratamiento génico
(TG) in vivo en los tumores subcutáneos de cáncer de pul-
món murino.
MATERIAL Y MÉTODOS: Se inyectaron a ratones C57BL/6
por vía subcutánea 5 × 105 células de la línea de cáncer de
pulmón murino de Lewis. A los 10 días se formaron tumores
subcutáneos de unos 5 mm de diámetro. En ese momento se
trataron mediante inyección intratumoral con un adenovi-
rus recombinante defectivo portador del gen de la timidinci-
nasa (AdCMV-Tk), o del gen de la interleucina 12
(AdCMV-IL12), o con células dendríticas (CD) singénicas
transducidas con el gen de la interleucina 12 (CD-IL12).
Como grupos control se incluyeron tumores tratados con
suero salino o con un adenovirus con el gen de la β-galacto-
sidasa (AdCMV-LacZ), que es un gen indicador sin efecto
terapéutico. El número de animales por grupo osciló entre
14 y 25 con adenovirus y entre 10 y 12 con CD. A continua-
ción se realizó un seguimiento del tamaño tumoral desde el
primer día de tratamiento hasta la tercera (adenovirus) o
cuarta (CD) semanas para comparar su evolución.
RESULTADOS: Se objetivó una disminución significativa del
crecimiento de los tumores subcutáneos en los grupos trata-
dos con AdCMV-Tk, AdCMV-IL12 y CD-IL12 comparados
con los grupos control tratados con suelo salino y AdCMV-
LacZ. En el grupo AdCMV-Tk esta diferencia fue estadísti-
camente significativa desde el día 7, en AdCMV-IL12 desde
el día 9 y en CD-IL12 desde el día 10 y se mantuvo hasta el
final del seguimiento.
CONCLUSIONES: El TG con AdCMV-Tk, AdCMV-IL12 o
CD-IL12 es efectivo en nuestro modelo de tumores subcutá-
neos de células de carcinoma pulmonar de Lewis, ya que es
capaz de disminuir su tasa de crecimiento de forma signifi-
cativa respecto a los grupos de control.
Palabras clave: Tratamiento génico. Cáncer de pulmón. Adeno-
virus. Timidincinasa. Interleucina 12. Células dendríticas.
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chemistry, molecular biology, biochemistry, cell
biology, genetics, and genetic engineering.2 It differs
from classical pharmacology in its use of genes and
vectors in place of other active molecules. To date, its
use has been studied most extensively in oncology,
particularly in relation to bronchogenic carcinoma.3
The vectors used can be classified as viral and
nonviral,4,5 and a large number of different genes can be
used for therapeutic purposes. In this study, we used a
viral vector, namely a first-generation, serotype 5,
replication-defective, recombinant adenovirus.6 The
virus is unable to replicate by itself since the part of the
genome necessary for replication is replaced with the
recombinant gene of interest. The genes used were
thymidine kinase (Tk) and interleukin 12 (IL-12).
Gene therapy for cancer utilizes various approaches,
and they can be combined and used alongside
conventional treatments.7 In this study, we used a suicide-
gene strategy with the gene for Tk and immunotherapy
with the gene for IL-12 and with dendritic cells
transduced with IL-12 (DC-IL12). Tk transforms
ganciclovir (GCV) into the highly cytotoxic GCV
triphosphate.8 Immunotherapy enhances the immune
response of the host to the tumor in order to eliminate it.
This can be achieved through the use of cytokines 
(IL-12)9 or by modifying immune cells (DC-IL12).10-12
In this study, we analyzed the usefulness of gene
therapy using suicide-gene and immunotherapy
strategies in a subcutaneous model of murine lung
cancer.
Material and Methods
Animals and Cell Lines
The female, 6-week-old, C57BL/6 mice (Harlan,
Barcelona, Spain) used in the study were cared for according
to current guidelines in our hospital.
Three human lung cancer cell lines (A549,
adenocarcinoma; HTB58, squamous cell carcinoma; and
H441, bronchioloalveolar adenocarcinoma) and 1 murine
lung cancer cell line (Lewis lung carcinoma, LLC) were used
for in vitro experiments. LLC, which is syngeneic with
C57BL/6 mice, was used for in vivo experiments. All cell
lines were obtained from the American Type Culture
Collection. LLC and A549 cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) and HTB58
and H441 were cultured in Roswell Park Memorial Institute
(RPMI) medium. Both media were supplemented with 10%
fetal bovine serum (FBS), 100 U/mL penicillin, and 
100 mg/mL streptomycin. Cultures were incubated at 37°C in
an atmosphere containing 5% CO2.
Adenovirus Construction
Adenoviruses were constructed containing the genes 
for Tk, IL-12, and Escherichia coli β-galactosidase.
β-galactosidase is a reporter gene used as a control and has no
therapeutic effect. All genes were placed under the control of
the ubiquitous cytomegalovirus (CMV) promoter. The viruses
were constructed according to a previously published
protocol13,14 in the laboratories of the Gene Therapy Unit,
Department of Internal Medicine, Clinica Universitaria de
Navarra, Spain.
Syngeneic Dendritic Cells
Bone marrow was taken from the femur and tibia of
syngeneic mice according to a previously published
protocol.15 Cells were infected in vitro with the adenovirus
AdCMV-IL12 at a multiplicity of infection (MOI) of 3000.
In Vitro Transduction of Cell Lines With AdCMV-LacZ
Cells from each cell line were seeded at a density of 2×105
cells in 2 mL of either DMEM or RPMI containing 2% FBS.
After 24 hours the medium was removed and the cells
infected with AdCMV-LacZ in a volume of 500 µL per well
of unsupplemented medium. After 4 hours, 1.5 mL of DMEM
or RPMI containing 2% FBS was added to the wells and the
cells were incubated for a further 48 hours. Infection was
performed at an MOI of 1, 10, 100, 1000, and 10 000. A
control well was prepared containing cells incubated in
DMEM without adenovirus infection. The medium was
removed after 2 days and the cells fixed with glutaraldehyde.
Following fixation, 500 µL of 5-bromo-4-chloro-3-indolyl-
beta-D-galactoside (X-gal) was added to each well and the
cells were incubated for 4 hours at 37°C. X-gal stains cells
blue if they contain β-galactosidase protein in their
cytoplasm. Thus, cells that are successfully transduced with
AdCMV-LacZ and contain the protein encoded by the
transgene will appear blue. The percentage transfection can
be assessed by optical microscopy to count the total number
of cells and the number of cells stained blue. This experiment
was performed twice and the number of transfected cells
counted in 5 fields per well.
In Vitro Transduction of LLC Cells With AdCMV-Tk
On day 1, 1.5×105 cells per well were seeded in 2 6-well
plates, each well containing 2 mL DMEM supplemented
with 2% FBS. On day 2, the cells were infected with
AdCMV-Tk by replacing the medium with 500 µL
unsupplemented DMEM at different MOIs. After 4 hours at
37°C, 1.5 mL of DMEM containing 2% FBS was added to
each well. During the next 5 days, the medium was replaced
daily. In one of the plates a fixed concentration of GCV 
(100 µmol/L) was used with varying MOI (10 000, 1000,
100, 10, and 1), while in the other, a fixed MOI of 100 was
used with GCV concentrations of 500, 250, 100, and 25
µmol/L. A control well was included in each plate. In the
first, the cells in the control well were treated with GCV but
were not infected with AdCMV-Tk. In the second, the cells
were infected with AdCMV-Tk but were not treated with
GCV. On day 7, the number of live cells was counted in each
well by exclusion of trypan blue. This experiment was
repeated twice to confirm the results.
In Vivo Transduction of Subcutaneous LLC Tumors 
With AdCMV-LacZ
Subcutaneous injections of 5×105 LLC cells were
administered in the flanks of 3 C57BL/6 mice. AdCMV-LacZ
was injected into the tumors when they reached a diameter of
5 mm. A dose of 1×109 plaque forming units (pfu) was used
in a volume of 40 µL physiologic saline. Animals were
sacrificed 2 days later and the subcutaneous tumors extracted.
The tumors were embedded in optimal cutting temperature
(OCT) compound (Tissue-Tek Sakura, Tokyo, Japan) and
frozen immediately in isopentane immersed in liquid
nitrogen. The samples were stored at –80oC. Tissue sections
were obtained with a cryostat. For staining, the sections were
first fixed in glutaraldehyde for 10 minutes and then washed
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twice with a phosphate-buffered solution before incubating
overnight in X-gal solution. The following day, the sections
were washed with a phosphate buffer and viewed under a
Nikon Eclipse E 800 optical microscope. Cells that were
transduced with the adenovirus were stained blue.
Subcutaneous Model and Treatment
Subcutaneous tumors were generated as described in the
previous section. When the tumors reached 5 mm in diameter,
they were injected with either adenovirus or dendritic cells.
Animals were anesthetized for tumor induction and treatment
by intraperitoneal injection of thiazine hydrochloride and
ketamine. Animals were divided into 4 groups for the
adenovirus experiment: 2 control groups, one treated with
physiologic saline (n=25 for Tk; n=16 for IL-12) and the
other with AdCMV-LacZ (n=23 for Tk; n=14 for IL-12), and
2 therapeutic groups, one treated with AdCMV-Tk (n=23)
and the other treated with AdCMV-IL12 (n=17). Treatments
were performed in 40 µL of physiologic saline. The
adenovirus doses used were 1×109 pfu in the Tk group, 5×108
pfu in the IL-12 group, and 1×109 or 5×108 pfu in the LacZ
group. The animals in the Tk group received GCV treatment
via daily intraperitoneal injection (50 mg/kg/day in a volume
of 200 mL physiologic saline) for 14 days, starting 2 days
after adenovirus injection. Two groups were formed for
experiments involving dendritic cells: a control group (n=10),
treated with physiologic saline, and a treatment group (n=12),
which received 5×105 DC-IL12 injected into the tumor in 75
µL of physiologic saline on day 1 and day 3. Tumor growth
was then followed and compared between groups by taking
measurements 3 times per week starting on the day of
treatment. Follow-up was undertaken for 21 days in the
experiment involving adenovirus and 28 days in the dendritic
cell experiment.
Statistical Analysis
Nonparametric methods were used for comparison of tumor
size. The Wilcoxon test was used for comparisons between 2
groups and the Friedman test for comparisons between more
than 2 groups. In all cases, P values less than or equal to .05
were considered statistically significant. Analysis was
performed with the Instat program (GraphPad Software Inc,
San Diego, USA).
Results
In Vitro Transduction of Cell Lines 
With AdCMV-LacZ
Prior to performing experiments in animals, the in
vitro transduction efficiency of AdCMV-LacZ was
assessed in various cell lines. The results are shown in
Table 1. The left hand column shows the MOI used 
and the remaining columns the percentage of
transduced cells in each cell line. The transduced cells
are stained blue with X-gal solution (Figure 1). All 4
cell lines were transduced by AdCMV-LacZ but the
efficiency varied. The most permissive cell line was
A549 and the most resistant, LLC, in which the first
blue-stained cells were observed at an MOI of 1000
and an MOI of 10 000 was required to achieve 42%
transduction.
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TABLE 1
In Vitro Transduction of Cell Lines With an Adenovirus
Carrying the Gene for β-Galactosidase (AdCMV-LacZ)*
MOI LLC H441 HTB58 A549
Control 0 0 0 0
1 0 1% 3% 5%
10 0 4% 20% 24%
100 0 29% 40% 90%
1000 15% 64% 100% 100%
10 000 42% 100% 100% 100%
*MOI indicates multiplicity of infection; LLC, Lewis lung carcinoma; HTB58,
squamous cell carcinoma; A549, adenocarcinoma; H441, bronchioloalveolar
adenocarcinoma.
TABLE 2
In Vitro Transduction of Lewis Lung Carcinoma Cells With
a Replication-Defective, Recombinant Adenovirus Carrying
the Gene for Thymidine Kinase (AdCMV-Tk)*
MOI of 100
Live Cells, % GCV, mmol/L
100 0
8.3 25
6.4 50
3.8 100
0.9 250
0.3 500
GCV, 100 mmol/L
Live Cells, % MOI
100 0
75 1
5 10
3.4 100
0 1000
0 10 000
*MOI indicates multiplicity of infection; GCV, ganciclovir.
Figure 1. Lewis lung carcinoma cells transduced in vitro with an
adenovirus carrying the gene for β-galactosidase (AdCMV-LacZ). The
image corresponds to a virus to cell ratio of 1000.
In Vitro Transduction of LLC Cells With AdCMV-Tk
The efficacy of the Tk-GCV system was tested in
vitro with the LLC line prior to its use in vivo. Table 2
shows the results obtained using a fixed MOI of 100
and a fixed dose of GCV of 100 mmol/L. With a fixed
MOI of 100, cell death was observed at all doses of
GCV tested. Cell death increased with increasing
concentration of the drug. With a fixed dose of 
100 mmol/L GCV, cell death occurred at all MOIs
tested, including the lowest MOI of 1. Cell death
increased with increasing MOI. The results obtained
with an MOI of 100 and 100 mmol/L GCV were similar
in both experiments: 3.8% and 3.4% live cells compared
with the control.
In Vivo Transduction of Subcutaneous LLC Tumors 
With AdCMV-LacZ
Tissue sections of subcutaneous tumors transduced with
AdCMV-LacZ were stained with X-gal (Figure 2). The
blue-stained cells transduced with the adenovirus were
visible along the trajectory of the needle in the tumor.
Treatment of Subcutaneous LLC Tumors 
With AdCMV-Tk
Tumor size was followed in 3 groups, treated with
physiologic saline, AdCMV-LacZ, and AdCMV-Tk. The
results are shown in Figure 3. The y axis shows the area of
the tumors (mm2) and the x axis shows the time elapsed.
Growth was slower in tumors treated with AdCMV-Tk
and GCV. Thus, the area of the tumors was smaller in that
group compared with those treated with physiologic saline
and AdCMV-LacZ. The differences began 2 days after
initiation of treatment and were statistically significant
from 7 days until the end of the study (P<.05). No
significant differences were observed between the groups
treated with physiologic saline and AdCMV-LacZ.
Treatment of Subcutaneous LLC Tumors 
With AdCMV-IL12
Tumor size was followed in 3 groups, treated with
physiologic saline, AdCMV-LacZ, and AdCMV-IL12.
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Figure 2. Subcutaneous tumor generated by Lewis lung carcinoma cells
in which the tumor was injected with an adenovirus carrying the gene for
β-galactosidase (AdCMV-LacZ).
Figure 3. Subcutaneous Lewis lung carcinoma tumors treated with
physiologic saline, adenovirus carrying the gene for β-galactosidase
(AdCMV-LacZ), or a replication-defective recombinant adenovirus
carrying the gene for thymidine kinase (AdCMV-Tk). Tumor area is
plotted against time. A significant delay in tumor growth is seen in the
group treated with AdCMV-Tk. *P<.05, from this point onwards.
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Figure 4. Subcutaneous Lewis lung carcinoma tumors treated with
physiologic saline, adenovirus carrying the gene for β-galactosidase
(AdCMV-LacZ), or a replication-defective recombinant adenovirus
carrying the gene for interleukin 12 (AdCMV-IL12). Tumor area is
plotted against time elapsed. A significant delay in tumor growth is seen
in the group treated with AdCMV-IL12. *P<.01, from this point onwards.
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The results are shown in Figure 4. The y axis shows the
area of the tumors (mm2) and the x axis shows the time
elapsed in days. Delayed tumor growth was observed in
the group treated with AdCMV-IL12 compared with the
other 2 groups. The differences became apparent on day
4 and were statistically significant from day 9 (P<.01).
No significant differences were observed between the
mice treated with physiologic saline and those treated
with AdCMV-LacZ.
Treatment of Subcutaneous LLC Tumors With DC-IL12
Two groups were used, one receiving injections of
physiologic saline and the other of DC-IL12 on days 1
and 3. Tumor size was then followed; the results are
shown in Figure 5. The y axis shows the area of the
tumors and the x axis shows the time elapsed from
initiation of treatment. Differences were observed
between the 2 groups starting on day 3, with a reduced
growth of the tumors treated with DC-IL12. The
differences were statistically significant from day 10
onwards (P<.05).
Discussion
In the last 60 years, lung cancer has moved from
being a relatively uncommon disease to become the
most common cancer in the world (12.3% of all
malignant tumors), with an estimated 1.2 million new
cases in the year 2000, 52% of which occurred in
developed countries.16 Given the low survival rate of
lung cancer patients treated conventionally, new
treatments must be sought. Gene therapy has emerged
in recent years as an alternative to more traditional
forms of treatment in bronchogenic carcinoma, such as
surgery, chemotherapy, or radiotherapy.7 The aim of this
study was to assess the efficacy of gene therapy in a
subcutaneous model of murine lung cancer.
The first step was to assess the efficacy of the system
in vitro. To this end, cultured LLC cells were infected
with AdCMV-LacZ. LLC cells were later used for in
vivo experiments. In addition, 3 human lung cancer cell
lines were analyzed. All of the cell lines could be
transduced using adenovirus-based gene therapy
techniques, but the efficiency varied according to the
cell line (Table 1 and Figure 1). Adenovirus enter cells
via endocytosis mediated by the coxsackievirus and
adenovirus receptor (CAR)17 and integrins αvβ3 and αvβ5
in the cell membrane.18 CAR binds the fibers projecting
from the adenovirus capsid and the integrins in the cell
membrane bind viral capsid proteins and internalize the
adenovirus in the cell.18 The transduction efficiency
depends on the number of membrane receptors for
adenovirus that the cells have, leading the efficiency to
vary according to the cell line used.19 Cells with a high
number of adenovirus receptors will display a high
transduction efficiency. The results obtained in this
study are similar to those published with other lung
cancer cell lines.20 The LLC cell line required an MOI
of 1000 before the first stained cells were visible and a
high MOI (10000) to achieve 42% transduction. These
infection ratios are high but are consistent with those
published previously for the LLC cell line, which was
reported to require an MOI of 20 500 to achieve a
transduction efficiency of 100%.21
The next step was to assess the efficacy of the Tk-
GCV system in vitro. This system employs the suicide
gene strategy mentioned in the Introduction. The
strategy involves introduction of the gene for Tk into
tumor cells in order for them to convert GCV, which is
nontoxic, into GCV triphosphate, which is highly
cytotoxic.8 In addition to being toxic for the transduced
cell, the effect extends to surrounding cells by diffusion
of GCV triphosphate through cell junctions. This is
known as the bystander effect and it amplifies the
efficacy of the system.22 LLC cells were infected in
culture with AdCMV-Tk using different MOIs followed
by a range of concentrations of GCV. The aim was to
determine whether introduction of the gene for Tk into
cultured LLC cells was effective and led to cell death
following treatment with GCV.13 The results showed
that this system worked (Table 2). Even at a low MOI
(1, 10, or 100), when transgene expression was not
observed with AdCMV-LacZ, cell death nevertheless
occurred with the Tk-GCV system. This finding is
explained by the low sensitivity of the LacZ reporter
gene used to assess adenovirus transduction and the
consequent tendency to underestimate transduction
levels. Cells can contain β-galactosidase protein in their
cytoplasm but not be stained blue with X-gal because
the amount of protein is small and the visualization
threshold is unable to distinguish it. Consequently,
although blue-stained cells were not observed with
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Figure 5. Subcutaneous Lewis lung carcinoma tumors treated with
physiologic saline or syngeneic dendritic cells transduced with the gene
for interleukin 12 (DC-IL12). Tumor area is plotted against time. Tumor
growth was significantly reduced in the group treated with DC-IL12.
*P<.05, from this point onwards.
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AdCMV-LacZ infected at MOIs of 100, 10, or 1, cell
death occurred with AdCMV-Tk and GCV, the action of
which would also be enhanced by the bystander
effect.12,21
The efficiency of AdCMV-LacZ transduction was
assessed for in vivo experiments by injection into
subcutaneous LLC tumors. Following staining, blue
cells were observed inside the tumor, mainly located
along the trajectory of the needle (Figure 2). The
efficiency in vivo depends on the dose of adenovirus
used, the promoter controlling the transgene, and the
injection technique. It is better to perform a single
injection in order for the adenovirus to diffuse as widely
as possible throughout the tumor, aided by the pressure
produced during injection. The integrity of the tumor
also affects the efficacy of the procedure, since if it is
poor the adenovirus can escape and infect peritumoral
tissue.23
Having confirmed that the adenovirus was able to
transduce subcutaneous tumors in vivo, the therapeutic
adenoviruses were studied. Physiologic saline,
AdCMV-LacZ, and AdCMV-Tk were injected into the
tumors. Tumor cells transduced with AdCMV-Tk
produce Tk and will transform GCV into GCV
triphosphate, which is toxic to dividing cells as a result
of its inhibition of DNA polymerase. Its effect is
enhanced by the bystander phenomenon, which also
functions in vivo.8,24 During follow-up, a reduction in
the growth of the tumors was observed in the group
treated with AdCMV-TK; this effect was apparent from
2 days after initiation of treatment. This coincided with
the first day of treatment with intraperitoneal GCV. The
differences increased and were statistically significant
from day 7 until the end of the study (Figure 3). No
toxicity due to administration of either the adenovirus
or GCV alone was observed at any time. Thus,
treatment with AdCMV-Tk and GCV causes a
significant reduction in the growth of tumors in this
model compared with those treated with saline or
AdCMV-LacZ.
In another group of animals the tumors were treated
with physiologic saline, AdCMV-LacZ, or AdCMV-
IL12. The aim was to enhance the immune response of
the host to the tumor in order to eliminate it. IL-12 was
used because it is able to activate both types of immune
response, namely innate and acquired immunity. In
addition, antitumor effects have been shown in animal
models: it impedes the growth of new tumors and
causes regression of those that are already
established.25-27 Delayed tumor growth was observed 4
days after injection of the adenovirus in the group
treated with AdCMV-IL12 compared with those treated
with either saline or AdCMV-LacZ. The differences
were statistically significant from day 9 onwards and
remained so until the end of the follow-up period
(Figure 4). No toxic side effects of treatment were
observed. AdCMV-IL12 was used at a dose of 5×108
pfu. Lower doses of 1×108 or 2.5×108 did not display
differences from the control groups treated with
physiologic saline or AdCMV-LacZ, while higher doses
(1×109 pfu) did not lead to greater benefits than 5×108
pfu (data not shown). The differences were apparent
from 4 days of treatment, 2 days later than with
AdCMV-Tk. This delay is due to the fact that the effects
of Tk following GCV administration are immediate,
whereas IL-12 induces a cascade of secondary
cytokines that are ultimately responsible for its biologic
effects and therefore delay its action.28 In conclusion, a
significant delay in the rate of growth of tumors in this
model is seen with treatment using AdCMV-IL12.
Finally, syngeneic dendritic cells transduced with
adenovirus in order that they secrete IL-12 were also
injected. Animals treated with physiologic saline were
used as controls. The dendritic cells in the cavity of the
tumor capture antigens and present them to the immune
system to initiate an antitumor response.10,12,15,29
Differences between the groups were observed at 3 days
of treatment, with lower growth in the group that
received DC-IL12. The differences were statistically
significant from day 10 onwards and remained so until
the end of the follow-up period (Figure 5). Thus,
treatment with DC-IL12 caused a significant reduction
in the growth of the subcutaneous tumors.
It can be concluded that the 3 treatments (AdCMV-
Tk plus GCV, AdCMV-IL12, and DC-IL12) were
effective in our in vivo model. Those treatments were
able to reduce the growth of subcutaneous tumors
compared with control groups (physiologic saline and
AdCMV-LacZ). Consequently, it can be envisaged that
in the future gene therapy will be employed as a new
treatment for lung cancer alongside conventional
treatments, although further studies and clinical trials
will be necessary.30
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